Published August 11, 2026
On June 4, 2026, the U.S. Judicial Panel on Multidistrict Litigation centralized federal lawsuits against Regeneron Pharmaceuticals, Sanofi-Aventis U.S., and Genzyme Corporation over the eczema and asthma drug Dupixent (dupilumab), creating MDL No. 3180 in the District of New Jersey before Judge Zahid N. Quraishi. The move consolidated 15 transferred cases, with several more identified as potential tag-along filings, into a single court for coordinated pretrial proceedings.
The lawsuits allege that Dupixent caused or accelerated cutaneous T-cell lymphoma (CTCL) and other T-cell lymphomas in some patients, and that its manufacturers either masked early warning signs of the disease or failed to adequately warn patients and doctors about the risk. Plaintiffs had filed cases across states including Georgia, California, Florida, Alabama, Illinois, New Jersey, Nevada, Pennsylvania, and Tennessee before the panel grouped them together.
An MDL doesn't decide who wins or loses. It simply moves shared pretrial work — evidence gathering, expert witness disputes, and early motions — in front of one judge instead of dozens, so cases with the same core allegations aren't relitigating the same ground separately across the country. Individual cases still keep their own facts and, eventually, their own trial dates; a small number are typically selected as bellwether trials to give both sides an early read on how juries respond to the evidence.
As of the MDL's formation, there have been no trials, verdicts, or nationwide settlements in the Dupixent litigation. The case is still in its early stages, and plaintiffs' firms continue to file and investigate new claims.
If you or a family member took Dupixent and were later diagnosed with cutaneous T-cell lymphoma or another T-cell lymphoma, see Atumio's Dupixent case page to learn more about who may be affected.